In vitro S100B secretion is reduced by apomorphine: Effects of antipsychotics and antioxidants

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 35, Issue 5, 2011, Pages 1291-1296

  Nardin, Patrícia ^a   Tramontina, Ana Carolina ^a   Quincozes Santos, André ^a   Tortorelli, Lucas S ^a   Lunardi, Paula ^a   Klein, Paulo R ^a   Wartchow, Krista M ^a   Bobermin, Larissa D ^a   Gottfried, Carmem ^a   Elisabetsky, Elaine ^a   Gonçalves, Carlos Alberto ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Antipsychotic; Apomorphine; Astrocyte; S100B; Schizophrenia

Indexed keywords

ADENYLATE CYCLASE; ANTIOXIDANT; APOMORPHINE; DOPAMINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; PROTEIN S100B; RISPERIDONE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BRAIN SLICE; CELL STRAIN C6; CONTROLLED STUDY; DRUG EFFECT; DRUG EXPOSURE; EX VIVO STUDY; FEMALE; GLIOMA CELL; HIPPOCAMPUS; IN VITRO STUDY; MACROGLIA; MALE; NONHUMAN; PROTEIN SECRETION; RAT; SCHIZOPHRENIA;

ANIMALS; ANTIOXIDANTS; ANTIPSYCHOTIC AGENTS; APOMORPHINE; ASTROCYTES; CELL CULTURE TECHNIQUES; CELL SURVIVAL; DOPAMINE AGONISTS; FEMALE; GLIOMA; HIPPOCAMPUS; L-LACTATE DEHYDROGENASE; MALE; NERVE GROWTH FACTORS; RATS; RATS, WISTAR; S100 PROTEINS; TUMOR CELLS, CULTURED;

EID: 79957788694     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2011.04.004     Document Type: Article

References (49)

1. Andreazza A.C., Cassini C., Rosa A.R., Leite M.C., de Almeida L.M., Nardin P., et al. Serum S100B and antioxidant enzymes in bipolar patients. J Psychiatr Res 2007, 41:523-529.
2. Artigas F. The prefrontal cortex: a target for antipsychotic drugs. Acta Psychiatr Scand 2010, 121:11-21.
3. De Keyser J., Mostert J.P., Koch M.W. Dysfunctional astrocytes as key players in the pathogenesis of central nervous system disorders. J Neurol Sci 2008, 267:3-16.
4. de Souza D.F., Leite M.C., Quincozes-Santos A., Nardin P., Tortorelli L.S., Rigo M.M., et al. S100B secretion is stimulated by IL-1beta in glial cultures and hippocampal slices of rats: Likely involvement of MAPK pathway. J Neuroimmunol 2009, 206:52-57.
5. Donato R., Sorci G., Riuzzi F., Arcuri C., Bianchi R., Brozzi F., et al. S100B's double life: intracellular regulator and extracellular signal. Biochim Biophys Acta 2009, 1793:1008-1022.
6. Gattaz W.F., Lara D.R., Elkis H., Portela L.V., Goncalves C.A., Tort A.B., et al. Decreased S100-beta protein in schizophrenia: preliminary evidence. Schizophr Res 2000, 43:91-95.
7. Goncalves D., Karl J., Leite M., Rotta L., Salbego C., Rocha E., et al. High glutamate decreases S100B secretion stimulated by serum deprivation in astrocytes. Neuroreport 2002, 13:1533-1535.
8. Goncalves C.A., Leite M.C., Nardin P. Biological and methodological features of the measurement of S100B, a putative marker of brain injury. Clin Biochem 2008, 41:755-763.
9. Goncalves C.A., Leite M.C., Guerra M.C. Adipocytes as an important source of serum S100B and possible roles of this protein in adipose tissue. Cardiovasc Psychiatry Neurol 2010, 790431.
10. Gottfried C., Cechin S.R., Gonzalez M.A., Vaccaro T.S., Rodnight R. The influence of the extracellular matrix on the morphology and intracellular pH of cultured astrocytes exposed to media lacking bicarbonate. Neuroscience 2003, 121:553-562.
11. Guillin O., Abi-Dargham A., Laruelle M. Neurobiology of dopamine in schizophrenia. Int Rev Neurobiol 2007, 78:1-39.
12. Gunduz-Bruce H. The acute effects of NMDA antagonism: from the rodent to the human brain. Brain Res Rev 2009, 60:279-286.
13. Han S.K., Mytilineou C., Cohen G. L-DOPA up-regulates glutathione and protects mesencephalic cultures against oxidative stress. J Neurochem 1996, 66:501-510.
14. Hansen M.B., Nielsen S.E., Berg K. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods 1989, 119:203-210.
15. Hara H., Ohta M., Adachi T. Apomorphine protects against 6-hydroxydopamine-induced neuronal cell death through activation of the Nrf2-ARE pathway. J Neurosci Res 2006, 84:860-866.
16. Hertz L., Schousboe I., Schousboe A. Receptor expression in primary cultures of neurons or astrocytes. Prog Neuropsychopharmacol Biol Psychiatry 1984, 8:521-527.
17. Khan Z.U., Koulen P., Rubinstein M., Grandy D.K., Goldman-Rakic P.S. An astroglia-linked dopamine D2-receptor action in prefrontal cortex. Proc Natl Acad Sci U S A 2001, 98:1964-1969.
18. Lara D.R., Gama C.S., Belmonte-de-Abreu P., Portela L.V., Goncalves C.A., Fonseca M., et al. Increased serum S100B protein in schizophrenia: a study in medication-free patients. J Psychiatr Res 2001, 35:11-14.
19. Leite M.C., Galland F., Brolese G., Guerra M.C., Bortolotto J.W., Freitas R., et al. A simple, sensitive and widely applicable ELISA for S100B: Methodological features of the measurement of this glial protein. J Neurosci Methods 2008, 169:93-99.
20. Leite M.C., Galland F., de Souza D.F., Guerra M.C., Bobermin L., Biasibetti R., et al. Gap junction inhibitors modulate S100B secretion in astrocyte cultures and acute hippocampal slices. J Neurosci Res 2009, 87:2439-2446.
21. Ling S.H., Tang Y.L., Jiang F., Wiste A., Guo S.S., Weng Y.Z., et al. Plasma S-100B protein in Chinese patients with schizophrenia: comparison with healthy controls and effect of antipsychotics treatment. J Psychiatr Res 2007, 41:36-42.
22. Mitchell E.S., Neumaier J.F. 5-HT6 receptor antagonist reversal of emotional learning and prepulse inhibition deficits induced by apomorphine or scopolamine. Pharmacol Biochem Behav 2008, 88:291-298.
23. Nardin P., Tramontina F., Leite M.C., Tramontina A.C., Quincozes-Santos A., de Almeida L.M., et al. S100B content and secretion decrease in astrocytes cultured in high-glucose medium. Neurochem Int 2007, 50:774-782.
24. Nardin P., Tortorelli L., Quincozes-Santos A., de Almeida L.M., Leite M.C., Thomazi A.P., et al. S100B secretion in acute brain slices: modulation by extracellular levels of Ca(2+) and K (+). Neurochem Res 2009, 34:1603-1611.
25. Ng F., Berk M., Dean O., Bush A.I. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J Neuropsychopharmacol 2008, 11:851-876.
26. Pillai A., Parikh V., Terry A.V., Mahadik S.P. Long-term antipsychotic treatments and crossover studies in rats: differential effects of typical and atypical agents on the expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. J Psychiatr Res 2007, 41:372-386.
27. Qi L.Y., Xiu M.H., Chen da C., Wang F., Kosten T.A., Kosten T.R., et al. Increased serum S100B levels in chronic schizophrenic patients on long-term clozapine or typical antipsychotics. Neurosci Lett 2009, 462:113-117.
28. Quincozes-Santos A., Abib R.T., Leite M.C., Bobermin D., Bambini-Junior V., Goncalves C.A., et al. Effect of the atypical neuroleptic risperidone on morphology and S100B secretion in C6 astroglial lineage cells. Mol Cell Biochem 2008, 314:59-63.
29. Roh K., Roh S., Yang B.H., Lee J.S., Chai Y.G., Choi M.R., et al. Effects of haloperidol and risperidone on the expression of heat shock protein 70 in MK-801-treated rat C6 glioma cells. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:1793-1797.
30. Rothermundt M., Missler U., Arolt V., Peters M., Leadbeater J., Wiesmann M., et al. Increased S100B blood levels in unmedicated and treated schizophrenic patients are correlated with negative symptomatology. Mol Psychiatry 2001, 6:445-449.
31. Rothermundt M., Ponath G., Arolt V. S100B in schizophrenic psychosis. Int Rev Neurobiol 2004, 59:445-470.
32. Rothermundt M., Ohrmann P., Abel S., Siegmund A., Pedersen A., Ponath G., et al. Glial cell activation in a subgroup of patients with schizophrenia indicated by increased S100B serum concentrations and elevated myo-inositol. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:361-364.
33. Sakatani S., Seto-Ohshima A., Shinohara Y., Yamamoto Y., Yamamoto H., Itohara S., et al. Neural-activity-dependent release of S100B from astrocytes enhances kainate-induced gamma oscillations in vivo. J Neurosci 2008, 28:10928-10936.
34. Sarandol A., Kirli S., Akkaya C., Altin A., Demirci M., Sarandol E. Oxidative-antioxidative systems and their relation with serum S100 B levels in patients with schizophrenia: effects of short term antipsychotic treatment. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:1164-1169.
35. Schmitt A., Bertsch T., Henning U., Tost H., Klimke A., Henn F.A., et al. Increased serum S100B in elderly, chronic schizophrenic patients: negative correlation with deficit symptoms. Schizophr Res 2005, 80:305-313.
36. Schroeter M.L., Steiner J. Elevated serum levels of the glial marker protein S100B are not specific for schizophrenia or mood disorders. Mol Psychiatry 2009, 14:235-237.
37. Schroeter M.L., Abdul-Khaliq H., Fruhauf S., Hohne R., Schick G., Diefenbacher A., et al. Serum S100B is increased during early treatment with antipsychotics and in deficit schizophrenia. Schizophr Res 2003, 62:231-236.
38. Schroeter M.L., Abdul-Khaliq H., Krebs M., Diefenbacher A., Blasig I.E. Neuron-specific enolase is unaltered whereas S100B is elevated in serum of patients with schizophrenia-original research and meta-analysis. Psychiatry Res 2009, 167:66-72.
39. Steiner J., Bernstein H.G., Bielau H., Berndt A., Brisch R., Mawrin C., et al. Evidence for a wide extra-astrocytic distribution of S100B in human brain. BMC Neurosci 2007, 8:2.
40. Steiner J., Walter M., Wunderlich M.T., Bernstein H.G., Panteli B., Brauner M., et al. A new pathophysiological aspect of S100B in schizophrenia: potential regulation of S100B by its scavenger soluble RAGE. Biol Psychiatry 2009, 65:1107-1110.
41. Steiner J., Schiltz K., Walter M., Wunderlich M.T., Keilhoff G., Brisch R., et al. S100B serum levels are closely correlated with body mass index: an important caveat in neuropsychiatric research. Psychoneuroendocrinology 2010, 35:321-324.
42. Steiner J., Schroeter M.L., Schiltz K., Bernstein H.G., Muller U.J., Richter-Landsberg C., et al. Haloperidol and clozapine decrease S100B release from glial cells. Neuroscience 2010, 167:1025-1031.
43. Steiner J., Walter M., Guest P., Myint A.M., Schiltz K., Panteli B., et al. Elevated S100B levels in schizophrenia are associated with insulin resistance. Mol Psychiatry 2010, 15:3-4.
44. Swerdlow N.R., Braff D.L., Taaid N., Geyer M.A. Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients. Arch Gen Psychiatry 1994, 51:139-154.
45. Tramontina F., Leite M.C., Goncalves D., Tramontina A.C., Souza D.F., Frizzo J.K., et al. High glutamate decreases S100B secretion by a mechanism dependent on the glutamate transporter. Neurochem Res 2006, 31:815-820.
46. Tramontina A.C., Tramontina F., Bobermin L.D., Zanotto C., Souza D.F., Leite M.C., et al. Secretion of S100B, an astrocyte-derived neurotrophic protein, is stimulated by fluoxetine via a mechanism independent of serotonin. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:1580-1583.
47. Trantham-Davidson H., Neely L.C., Lavin A., Seamans J.K. Mechanisms underlying differential D1 versus D2 dopamine receptor regulation of inhibition in prefrontal cortex. J Neurosci 2004, 24:10652-10659.
48. Wang M., Yao Y., Kuang D., Hampson D.R. Activation of family C G-protein-coupled receptors by the tripeptide glutathione. J Biol Chem 2006, 281:8864-8870.
49. Wiesmann M., Wandinger K.P., Missler U., Eckhoff D., Rothermundt M., Arolt V., et al. Elevated plasma levels of S-100b protein in schizophrenic patients. Biol Psychiatry 1999, 45:1508-1511.